

Products Developed Against International Innovator



MOLECULE	API	BE REFERENCE PRODUCT	COUNTRIES REGISTERED IN	COUNTRIES COMMERCIALIZED IN
Anti Diabetic				
Gliclazide 30/60 mg MR Tablets	CEP	Diamicon® Gliclazide MR Tablets 30, 60 mg (Servier, UK)	Under Development	-
Metformin HCl 500 mg ER USP Tablets	DMF	Glucophage® Metformin HCl XR Tablets 500 mg (BMS, US)	US (2012) UAE (2018), South Africa (Under registration)	US (2013)
Metformin HCl 750 mg ER USP Tablets	DMF	Glucophage® Metformin HCl XR Tablets 750 mg (Merck, Malaysia)	Guatemala (2014), Philippines (2016), Malaysia (Under registration), Peru (2016), Vietnam (2016), Kazakhstan (2018), Myanmar (2017), Tanzania (2019), Uganda (Under registration)	Guatemala (2014), Vietnam (2017), Peru (2017), Myanmar (2018)
Metformin HCl 1000 mg PR Tablets	CEP	Glucophage® Metformin HCl SR Tablets 1000 mg PR (Merck, UK)	UK (Under registration), Italy (Under registration), Netherlands (Under registration), Poland (Under registration)	-
Metformin HCl 500 mg PR Tablets	CEP	Glucophage® Metformin HCl SR Tablets 500 mg PR (Merck, UK)	UK (Under registration), Italy (Under registration), Netherlands (Under registration), Poland (Under registration)	-
Metformin HCl 750 mg PR Tablets	CEP	Glucophage® Metformin HCl SR Tablets 750 mg PR (Merck, UK)	UK (Under registration), Italy (Under registration), Netherlands (Under registration), Poland (Under registration)	-
Metformin 500 mg/1000 mg ER Tablets	DMF	Glumetza Metformin HCl ER Tablets (Valeant Pharmaceutical International, Inc., US)	Under Development	-
Metformin 500 mg/1000 mg ER Tablets	DMF	Fortamet Metformin HCl ER Tablets (Actavis Laboratories FL, Inc., US)	Under Development	-
Dapagliflozin 5mg/10mg Tablets	DMF	Farxiga® Dapagliflozin Tablets 10mg (AstraZeneca, US)	US (Tentative approval received 2019)	-
Gastrointestinal				
Lansoprazole 15/30 mg DR Capsules	DMF	Prevacid® Lansoprazole DR Capsules 30 mg (Takeda, US)	US (2017)	US (2018)
Mesalamine 1.2 g DR Tablets	DMF	Lialda® Mesalamine DR Tablets 1.2 g (Shire, US)	Under Development	-
Cardiovascular				
Amlodipine + Telmisartan 5/40, 5/80, 10/40, 10/80 mg Tablets	CEP + ASMF	Twynsta® Tablets (Boehringer Ingelheim, Austria)	Under Development	-
Chlorthalidone 25mg/50 mg Tablets	DMF	Chlorthalidone Tablets (Mylan, US)	US (Filed 2018)	-
Colesevelam Hydrochloride Tablets 625mg	DMF	Welchol Colesevelam HCL (Daiichi Sankyo, US)	US (Filed 2018)	-
Felodipine 2.5/5/10 mg ER Tablets	DMF	Plendil® Felodipine ER Tablets 10 mg (AstraZeneca LP, UK)	Vietnam (Under Registration)	-
Metoprolol 25/50/100/200 mg ER Tablets	DMF	Toprol XL® Metoprolol ER Tablets 200 / 50 mg (Astrazeneca, US)	US (Filed 2013)	-
Olmesartan Medoxomil 5/20/40 mg Tablets	DMF	Benicar® Olmesartan Medoxomil Tablets 40 mg (Daiichi Sankyo, US)	US (Filed 2016)	-

* PERMEABILITY STUDY

CONFIDENTIAL VERSION 1.9

NOTE: This brochure is NOT AN OFFER FOR SALE by Inventia Healthcare Limited. Products protected by valid patents are not offered for sale in countries where the sale of such products constitute patent infringement. Products protected by patents will not be supplied where the patent is valid. Any reference to "patents" includes Supplementary Protection Certificate (SPC's) for the product protected by those patents.

Products Developed Against International Innovator

continued



MOLECULE	API	BE REFERENCE PRODUCT	COUNTRIES REGISTERED IN	COUNTRIES COMMERCIALIZED IN
Cardiovascular				
Rosuvastatin 5/10/20/40 mg Tablets	DMF	Crestor® Rosuvastatin Tablets 40 mg (Astra Zeneca, US)	US (Filed 2014), Chile (Under Registration)	-
Telmisartan 20/40/80 mg Tablets	DMF	Micardis® Telmisartan Tablets 80 mg (Boehringer Ingelheim,US)	US (2015), UAE (2018), India (2018)	US (2016),India (2018)
Telmisartan + Hydrochlorothiazide 40/12.5, 80/12.5, 80/25 mg Tablets	DMF	Micardis HCT® Telmisartan 80 mg & Hydrochlorothiazide Tablets 25 mg (Boehringer Ingelheim,US)	US (Filed 2016) Kazakhstan (Under Registration)	-
Rivaroxaban 2.5/10/15/20 mg Tablets	ASMF	Xarelto® Rivaroxaban Film-Coated Tablets 10 & 20 mg (Bayer Pharma,UK)	Under Development	-
CNS				
Buspirone HCl Tablets 5 mg / 7.5 mg/ 10mg/ 15mg/ 30 mg	DMF	Buspirone HCl Tablets (Teva, US)*	US (2018)	US (2018)
Carbamazepine ER Tablets 100 mg/ 200 mg/ 400 mg	DMF	Tegretol® ER Tablets (Novartis, US)	Under Development	-
Duloxetine 30/60 mg GR Capsules	EUDMF	Cymbalta® Duloxetine HCl GR Capsules 60 mg (Eli Lilly, Netherland)	UK and Malta (Filed 2015), Spain and Portugal (Filed 2019) UAE (Under registration), Chile (Under registration)	UK (2018)
Fluoxetine Tablets 60 mg	DMF	Fluoxetine Tablets, USP (Edgemont, US)	US (2017)	US (2018)
Iloperidone 1/2/4/6/8/10/12 mg Tablets	DMF	Fanapt® Iloperidone Tablets 1 mg (Novartis, US)	US (2016)	-
Paliperidone 1.5/3/6/9 mg ER Tablets	DMF	Invega® Paliperidone ER Tablet 6 mg (Janssen L.P.,US)	US (2019)	-
Venlafaxine 37.5/75/150 mg ER Capsules	DMF	Effexor® Venlafaxine HCl ER Capsules 150 mg (Pfizer,US)	US (Filed 2011)	-
Urinogenital				
Darifenacin Hydrobromide 7.5/15 mg ER Tablets	DMF	Enablex® Darifenacin ER Tablets 15 mg (Novartis, US)	US (Filed 2013), Colombia (Under Registration)	-
Tolterodine Tartrate 2/4 mg ER Capsules	DMF	Detrol® Tolterodine ER Capsules 4 mg (LA by Pharmacia Upjohn of Pfizer NY,US)	US (Filed 2012)	-
Nitrofurantoin:Nitrofurantoin Macrocrystals Capsules 75:25mg	DMF	Macrobid® Capsules (Alvogen Inc, US)	US (Filed 2018)	-
Nitrofurantoin 100mg Prolonged Release Capsules	ASMF	Macrobid Prolonged-Release Capsules 100mg (Mercury Pharmaceuticals Ltd, UK)	Under Development	-
Anti infective				
Posaconazole Delayed Release Tablet 100mg	DMF	Noxafil® DR Tablets (Merck & Co, US)	Under Development for US	-
Posaconazole 100 mg GR Tablets	DMF	Noxafil® GR Tablets (Merck & Co, Germany, UK)	Under Development for EU	-
Pain Management				
Cyclobenzaprine HCl 15 mg/ 30 mg ER Capsules	DMF	Amrix® Cyclobenzaprine HCl ER Capsules 30 mg (Cephalon, US)	US (Filed 2018)	-

* PERMEABILITY STUDY

CONFIDENTIAL VERSION 1.9

NOTE: This brochure is NOT AN OFFER FOR SALE by Inventia Healthcare Limited. Products protected by valid patents are not offered for sale in countries where the sale of such products constitute patent infringement. Products protected by patents will not be supplied where the patent is valid. Any reference to "patents" includes Supplementary Protection Certificate (SPC's) for the product protected by those patents.

Products Developed Against International Innovator

continued



MOLECULE	API	BE REFERENCE PRODUCT	COUNTRIES REGISTERED IN	COUNTRIES COMMERCIALIZED IN
Pain Management				
Etoricoxib 30 mg / 60 mg/ 90 mg/120 mg Tablets	ASMF	Arcoxia Etoricoxib film coated Tablets 30mg, 60mg, 90mg and 120mg (MSD SHARP & DOHME GMBH, Germany)	Under Development	-
Heavy metal chelator				
Deferasirox 90 mg/ 180 mg/ 360 mg Film Coated Tablets	DMF, ASMF	Exjade Deferasirox Film coated 90 mg, 180 mg & 360 mg Tablets (Novartis Europharm Limited)	Under Development	-
Smoking cessation				
Varenicline Tartrate 0.5 mg/ 1 mg Tablets	CEP	Champix (Pfizer, EU)*	Under Development for EU	-
Varenicline Tartrate 0.5 mg/ 1 mg Tablets	DMF	Chantix (Pfizer, US)*	Under Development for US	-

* PERMEABILITY STUDY

CONFIDENTIAL VERSION 1.9

NOTE: This brochure is NOT AN OFFER FOR SALE by Inventia Healthcare Limited. Products protected by valid patents are not offered for sale in countries where the sale of such products constitute patent infringement. Products protected by patents will not be supplied where the patent is valid. Any reference to "patents" includes Supplementary Protection Certificate (SPC's) for the product protected by those patents.